ORIC Pharmaceuticals, Inc. ORIC

ORIC Company Overview

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies designed to overcome mechanisms of resistance in cancer treatment. The company operates within the biotechnology and oncology drug development industries, with a strategic emphasis on precision medicines that address tumor resistance to targeted therapies. ORIC’s core value proposition centers on targeting key resistance pathways that limit the durability and effectiveness of existing cancer treatments.

Founded in 2014, ORIC Pharmaceuticals evolved from an early-stage research company into a publicly traded clinical-stage organization following its initial public offering in 2020. Since inception, the company has concentrated on building a diversified oncology pipeline aimed at genetically defined cancers, leveraging insights into tumor biology and adaptive resistance. Its positioning is differentiated by a resistance-focused development strategy rather than targeting primary oncogenic drivers alone.